|
Jan 1
|
Institutions own 18% of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) shares but private equity firms control 52% of the company
|
|
Aug 10
|
NewAmsterdam Pharma First Half 2023 Earnings: €0.92 loss per share (vs €1.50 profit in 1H 2022)
|
|
Aug 7
|
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights
|